All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During the EHA 2022 Congress, the AML Hub was pleased to speak with Hee-Je Kim, The Catholic University of Korea, Seoul, KR, about the initial findings from the QuANTUM-First trial.
The QuANTUM-First study
Kim discusses the phase III study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy, in patients with newly diagnosed FLT3-ITD AML. Kim outlines the study details, as well as results and comparisons of overall survival, complete remission rates, and study limitations.
Quizartinib granted approval in Japan for the treatment of patients with newly diagnosed AML with FLT3-ITD mutations
On May 25, 2023, quizartinib, an oral, highly potent, and selective type II FLT3 inhibitor, was approved by Japan’s Ministry of...
What is the clinical significance of co-mutational patterns in AML?
During the EHA 2022 Congress, the AML Hub spoke with Brian Huntly, University of Cambridge, Cambridge, UK. We asked, What is the clinical significance of co-mutational patterns in...
Subscribe to get the best content related to AML delivered to your inbox